When *eCAM* was first born in 2004 we recognized our role in the world of integrative medicine, which is to become the model publication devoted to evidence-based approaches, thus the name 'evidence based'. Recognition was given to the fact that *eCAM* is a part of a larger compendium of information, technologies and ideas that increasingly overlap and intertwine in a tangled web of biological processes. There are sometimes interfacing and even colliding influences that include the forces of culture, habits and attitudes that can often snuff out, smother or mask the urgencies of viewing phenomena as biological or biomedical. Yet a crucial view prevails: we seek to fine-tune approaches that could yield analyses of evidence and ultimately to define mechanisms. Certain chronic ailments, but perhaps not acute problems, are the ripest for this modern excursion into integrative medicine.

In my first editorial, I proposed that *eCAM*, when rigorous, can be science ([@B1]). Happily, this created a stir and the beginnings of a barrage of invitations to somewhat exotic nations that are the cradles of integrative approaches: Ayurveda ([@B2; @B3; @B4]), Traditional Chinese Medicine (TCM) ([@B5; @B6; @B7]), Kampo ([@B8; @B9; @B10]) and Traditional Arabic and Islamic Medicine ([@B11], [@B12]). These travels were both inspiring, enlightening and a source for viewing integrative medicine in the larger human and multicultural context. With a constant vision of *eCAM* as a spin-off from biology, I assumed that the publication of rigorously reviewed papers could be mixed, i.e. those dealing strictly with animal models (basic science) and human trials (clinical analyses), both of which often involve *in vitro* approaches. I held this view through volumes 1--3. However, in volume 4, I decided to perhaps change the focus of reader\'s attention and to accomplish this, I chose to group the basic science papers together and the clinical analyses together, maintaining the subjects but as distinct and separate categories---nothing wrong with that! We classify all the time, art, music, animals, plants, cultures, etc. In addition, I've published our first supplement ([@B13]).

However, I did have another vision and that was to determine if this separation might draw readers' attention to the need for and the active recruiting of clinical papers. After all *eCAM*\'s title says it all: '*evidence based*' complementary and alternative medicine. So the instructions to authors were rewritten to include quite detailed ways to present clinical data (brief case reports; to develop case reports with detailed, illustrative documentation; case reports expanded into hypotheses; clinical studies with as strong an evidence base as possible, etc.) ([@B14]). Moreover, there were other efforts. I was invited to present Writer\'s Workshops at several national meetings of the American College for Advancement in Medicine ([@B15; @B16; @B17; @B18]), opening the doors for the works of clinicians. Instructions in *eCAM* and Writers' Workshops were international, national and local. Moreover, there were policy-structured international efforts in conjunction with the World Health Organization ([@B19]). These were meetings designed exclusively for veterinarians recognizing the utility of animal models in the quest to understand human disease ([@B20; @B21; @B22]).

Now, here are the results of this five-year strategy, mixing and separating basic science and clinical analyses in volumes 1--5. From a cursory examination, there seemed to be no significant differences in the numbers of basic science papers *vis-á-vis* the clinical analyses in volumes 1--3. In volume 4 however, there was twice-higher the number of basic science papers compared with clinical analyses. It was with volume 4 that the first separation began and that situation has prevailed in volume 5. Thus, despite efforts to raise the number and quality of clinical submissions, it seems that basic science papers outnumber the clinical papers in the two most recent volumes 4 and 5 of *eCAM*, where there was the separation and, presumably, greater visibility. This raises the question---do authors view *eCAM* as devoted more to basic science and to do credible work is easier in that sphere to accomplish than clinical approaches?

Now with volume 6, I question whether this seeming trend (i.e. toward more basic science papers) in *eCAM* is a reflection of a national and international trend. Was *eCAM*\'s vision to recognize itself as a scientific journal that lays a foundation for clinical analyses the appropriate and meaningful way to visualize itself? Despite this covert attempt in comparison with the more direct ones, do the rigors and flavors of science dominate and embellish *eCAM*\'*s* strength and existence ([@B23])?

Fortunately, the magazine *Science* may have a partial answer and present clues to questions surrounding clinical papers (*Science* 322: \#5899: 149--328; October 10, 2008). Biomedical funding is in trouble and that is a cause for alarm in preparing our world\'s scientists. However, I have been struck by a strong publication devoted to the subject of clinical applications in a special issue: 'Clinical Trials and Tribulations'. This opens with an introduction by Eliot Marshall entitled 'Lemons, Oranges and Complexity'. A provocative cover shows a white-coated investigator pushing a gargantuan white pill up a mountain. Upon first seeing it, one is not clear if the mountain is made of blue rocks or piles of blue paper---in either case, in my opinion, piles of papers (*qua* bureaucracy) are as difficult to surmount or conquer as piles of rocks! According to the description of the cover: 'Steep terrain': to move a therapy from the research lab to the doctor\'s office requires a huge investment in clinical trials, which are growing more costly and more complex every year. Five pertinent topics are treated and online material can be viewed at: [www.sciencemag.org/clinicaltrials](http://www.sciencemag.org/clinicaltrials). So for *eCAM*, it seems that a clear message may be emerging. There is a continuing place for basic science and for clinical analyses. Basic science under girds the successful attempt at translation from the bench to the clinic. We need it all: animal models, *in vitro* assays and carefully monitored clinical applications. At the same time, there should be an ever reminder of the paper of Goldrosen and Strauss ([@B24]) that presented the pyramid: the base or foundation, case reports and the pinnacle: randomized, controlled, double-blinded trials. This is an essential hierarchy in approaching biomedical research.
